Pfizer (NYSE:PFE) recently posted its Q2 results, which were above street estimates. The company’s overall sales grew 4% while adjusted earnings per share grew 21%. As expected, the company saw higher sales for Ibrance, Eliquis, and Xeljanz, which aided the overall earnings growth. Looking forward..
